Drilldown: Medicines
Medicines > generic:
None 
& routes :
Intravenous (continuous infusion in a REMS-certified facility) or
Subcutaneous
& routes :
Intravenous (continuous infusion in a REMS-certified facility) or
Subcutaneous Use the filters below to narrow your results.
generic: (Click arrow to add another value)
brand:
classes:
mechanism:
None (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)
uses:
starting dose:
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
70 mg SC monthly; may increase to 140 mg monthly (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)
preparations:
fda max:
routes: (Click arrow to add another value)
onset:
halflife:
bioavailability:
pregnancy:
Showing below up to 4 results in range #1 to #4.